News Digest / Ticker: ENGNW

Ticker: ENGNW

05:07pm, Thursday, Sep 11, 2025

enGene ramps R&D for detalimogene; $225M liquidity but rising burn, debt and governance risks

Quick take - enGene Holdings Inc. (NASDAQ: ENGNW) Clinical‑stage biotech advancing its lead candidate detalimogene in the Phase 1/2 LEGEND program and preparing a planned BLA filing in 2H 2026. Financials show a deliberate ramp in R&D and headcount, funded by cash + marketable securities, a term ...

09:00am, Thursday, Jun 12, 2025

enGene Holdings Reports Rising Losses Amid Focus on Bladder Cancer Gene Therapy Development

05:02pm, Monday, Mar 10, 2025

enGene Holdings Reports Rising Losses Amidst Promising R&D Progress in Q1 2025